You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

✉ Email this page to a colleague

« Back to Dashboard

United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

Docket	⤷ Sign Up	Date Filed	2021-04-01
Court	District Court, D. Delaware	Date Terminated	2022-05-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ANI PHARMACEUTICALS, INC.; UNITED THERAPEUTICS CORPORATION
Patents	7,417,070; 7,544,713; 8,252,839; 8,349,892; 8,410,169; 8,747,897; 9,050,311; 9,278,901; 9,393,203; 9,422,223; 9,593,066; 9,604,901
Attorneys	Karen Elizabeth Keller
Firms	Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP
Link to Docket	External link to docket

Small Molecule Drugs cited in United Therapeutics Corporation v. ANI Pharmaceuticals, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for United Therapeutics Corporation v. ANI Pharmaceuticals, Inc. (D. Del. 2021)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-04-01	1	Complaint	seq., involving United States Patent Nos. 7,417,070 (“the ’070 patent”) (attached as Exhibit A hereto…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’…the ’070 patent, the ’713 patent, ’839 patent, the ’892 patent, the ’169 patent, the ’897 patent, the ’	External link to document
2021-06-23	16	Scheduling Order - Patent	United States Patent Nos. 7,417,070 (“the ’070 patent”), 7,544,713 (“the ’713 patent”), 8,252,839 (“…(“the ’839 patent”), 8,349,892 (“the ’892 patent”), 8,410,169 (“the ’169 patent”), 8,747,897 (“the ’897…’897 patent”), 9,050,311 (“the ’311 patent”), 9,278,901 (“the ’901 patent”), 9,393,203 (“the ’203 patent…United States Patent Nos. 9,593,066 (“the ’066 patent”) and 9,604,901 (“the ’4901 patent”) are asserted…patent”), and 9,422,223 (“the ’223 patent”) Case 1:21-cv-00489-RGA Document 16 Filed 06/23/21 Page 4 of	External link to document
2022-05-26	48	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,070 B2; 7,544,713 B2; 8,252,839… 2021 26 May 2022 1:21-cv-00489 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.